Literature DB >> 22510884

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.

Michael Röring1, Ricarda Herr, Gina J Fiala, Katharina Heilmann, Sandra Braun, Anja E Eisenhardt, Sebastian Halbach, David Capper, Andreas von Deimling, Wolfgang W Schamel, Darren N Saunders, Tilman Brummer.   

Abstract

The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild-type B-Raf (B-Raf(wt)) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B-Raf(wt) and several of its gain-of-function (g-o-f) mutants. In contrast, the B-Raf(V600E), B-Raf(insT) and B-Raf(G469A) oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B-Raf(wt), B-Raf(V600E) displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B-Raf(wt) and Raf-1(wt) mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf-1 by kinase-inactivated B-Raf require an intact DIF. Surprisingly, the B-Raf DIF is not required for dimerisation between Raf-1 and B-Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two-step mechanism consisting of dimerisation and DIF-dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras-driven Raf-mediated (paradoxical) ERK activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510884      PMCID: PMC3365413          DOI: 10.1038/emboj.2012.100

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  92 in total

1.  Drug discovery: inhibitors that activate.

Authors:  Karen Cichowski; Pasi A Jänne
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

Review 2.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

Review 3.  KSR and CNK: two scaffolds regulating RAS-mediated RAF activation.

Authors:  A Clapéron; M Therrien
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

4.  Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling.

Authors:  Tilman Brummer; Peter E Shaw; Michael Reth; Yukiko Misawa
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

5.  Regulation of Raf-1 activation and signalling by dephosphorylation.

Authors:  Amardeep S Dhillon; Sharon Meikle; Zihni Yazici; Manfred Eulitz; Walter Kolch
Journal:  EMBO J       Date:  2002-01-15       Impact factor: 11.598

6.  Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.

Authors:  T Brummer; P Martin; S Herzog; Y Misawa; R J Daly; M Reth
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

7.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

Authors:  S Shirasawa; M Furuse; N Yokoyama; T Sasazuki
Journal:  Science       Date:  1993-04-02       Impact factor: 47.728

8.  Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer.

Authors:  Takashi Kubo; Yukie Kuroda; Akiko Kokubu; Fumie Hosoda; Yasuhito Arai; Nobuyoshi Hiraoka; Setsuo Hirohashi; Tatsuhiro Shibata
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

9.  Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.

Authors:  Daniel A Ritt; Daniel M Monson; Suzanne I Specht; Deborah K Morrison
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  63 in total

1.  Therapeutics: iterations of BRAF.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2012-05-24       Impact factor: 60.716

2.  Knock-in(g) RAF for a loop.

Authors:  Andrea Varga; Manuela Baccarini
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

3.  The importance of Raf dimerization in cell signaling.

Authors:  Alyson K Freeman; Daniel A Ritt; Deborah K Morrison
Journal:  Small GTPases       Date:  2013-08-28

4.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

Review 5.  Regulation of RAF protein kinases in ERK signalling.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05       Impact factor: 94.444

Review 6.  Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.

Authors:  Narittee Sukswai; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 7.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

8.  Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation.

Authors:  Michael Grasso; Michelle A Estrada; Christian Ventocilla; Minu Samanta; Jasna Maksimoska; Jessie Villanueva; Jeffrey D Winkler; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2016-09-06       Impact factor: 5.100

9.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Authors:  Zoi Karoulia; Yang Wu; Tamer A Ahmed; Qisheng Xin; Julien Bollard; Clemens Krepler; Xuewei Wu; Chao Zhang; Gideon Bollag; Meenhard Herlyn; James A Fagin; Amaia Lujambio; Evripidis Gavathiotis; Poulikos I Poulikakos
Journal:  Cancer Cell       Date:  2016-08-11       Impact factor: 31.743

10.  Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.

Authors:  Martin Köhler; Michael Röring; Björn Schorch; Katharina Heilmann; Natalie Stickel; Gina J Fiala; Lisa C Schmitt; Sandra Braun; Sophia Ehrenfeld; Franziska M Uhl; Thorsten Kaltenbacher; Florian Weinberg; Sebastian Herzog; Robert Zeiser; Wolfgang W Schamel; Hassan Jumaa; Tilman Brummer
Journal:  EMBO J       Date:  2015-12-10       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.